Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05184192 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT05184192 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 68 participants.
The verdict
NCT05184192, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
This study will investigate the efficacy of oral gabapentin in olfactory improvement following Covid-19- associated olfactory dysfunction. This is a randomized, double-blinded, placebo-controlled trial.
Interventions
- DRUG Placebo
- DRUG Gabapentin gelatin capsules 300mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2022-01-10 |
| Est. Completion | 2023-08-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05184192
The ClinicalTrials.gov registry entry for NCT05184192 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05184192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05184192 about?
NCT05184192 is a clinical study titled "Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction". This study will investigate the efficacy of oral gabapentin in olfactory improvement following Covid-19- associated olfactory dysfunction. This is a randomized, double-blinded, placebo-controlled trial.
What is the current status of trial NCT05184192?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2022-01-10. Estimated completion is 2023-08-29.
What interventions are being tested in trial NCT05184192?
The interventions under investigation include: Placebo (DRUG), Gabapentin gelatin capsules 300mg (DRUG).
Who is sponsoring clinical trial NCT05184192?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.